NCT03208218View on ClinicalTrials.gov

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 17, 2016

Primary Completion Date

August 25, 2016

Study Completion Date

October 31, 2016

Conditions

Healthy, Male

Interventions

DRUG

SYP-1512

Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)

DRUG

Revlimid cap

Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)

All Listed Sponsors

collaborator

Chungnam National University Hospital

OTHER

lead

Samyang Biopharmaceuticals Corporation

INDUSTRY

NCT03208218 - Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter